We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Fosun Pharma Buys Alma Lasers

By HospiMedica International staff writers
Posted on 13 May 2013
Fosun Pharma (Shanghai, China) will spend USD 240 million to acquire up to 96.6% of Alma Lasers (Caesarea; Israel), a manufacturer of lasers used in cosmetic surgery.

Through the transaction—Fosun Pharma’s first international healthcare acquisition project—the company aims to achieve an important milestone in its strategy of developing a global business, following its initial public offering (IPO) on the H share market in Hong Kong in 2012. More...
Fosun Pharma plans to continue its strategy of moving from product distribution to R&D and manufacturing, and gain a leading position in the international aesthetic medical device market segment.

Alma Lasers is an energy based (light, laser, radio frequency, and ultrasound) device manufacturer, with a comprehensive product offering and international sales network. Alma Lasers has developed world-class R & D capabilities in medical and cosmetic energy-based devices, as well as a leading brand name, recording nearly USD 100 million dollars total revenue in 2012; according to independent third-party research, the company has an overall 15% market share in the global high-end esthetic energy-based device segment.

“We are very optimistic about the growth prospects of the global medical and cosmetic energy-based device market, especially in the Brazil, Russia, India, and China, as well as other emerging markets,” said Qiyu Chen, chairman of Fosun Pharma. “Fosun Pharma will build on Alma's strength and be committed to developing a high-end medical device research, manufacturing platform. The acquisition demonstrates Fosun Pharma’s strategy in pursuit of global expansion.”

“Fosun's successful international M&A experience and strategic focus on healthcare and aesthetic and medical devices provide Alma Lasers with an exceptional platform to grow our business in Asia and globally,” said Ziv Karni, CEO of Alma Lasers. “We look forward to working with the management team of Fosun and benefiting from their expertise.”

Related Links:

Fosun Pharma
Alma Lasers



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
Premium Air-Mattress
MA-51
External Defibrillator
HeartSave Y | YA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.